

MEDNAX, INC.
RECONCILIATION OF INCOME FROM CONTINUING OPERATIONS
TO ADJUSTED EBITDA FROM CONTINUING OPERATIONS ATTRIBUTABLE TO MEDNAX, INC.
(in thousands)
(Unaudited)

	Three Months Ended June 30,	
	2021	2020
Income from continuing operations attributable to Mednax, Inc.	\$ 30,533	\$ 7,084
Interest expense	16,879	28,265
Gain on sale of building	(7,280)	-
Income tax provision	7,363	3,097
Depreciation and amortization expense	8,106	6,751
Transformational and restructuring related expenses	9,932	10,479
Adjusted EBITDA from continuing operations attributable to Mednax, Inc.	<u>\$ 65,533</u>	<u>\$ 55,676</u>

	Six Months Ended June 30,	
	2021	2020
Income (loss) from continuing operations attributable to Mednax, Inc.	\$ 35,885	\$ (11,415)
Interest expense	34,524	55,930
Gain on sale of building	(7,280)	-
Loss on early extinguishment of debt	14,532	-
Income tax provision	2,408	4,182
Depreciation and amortization	16,137	13,554
Transformational and restructuring related expenses	14,810	26,555
Adjusted EBITDA from continuing operations attributable to Mednax, Inc.	<u>\$ 111,016</u>	<u>\$ 88,806</u>